Every AAS community has its horror stories about Superdrol and Halotestin. Liver values in the thousands. HDL in the single digits. Hospital visits for athletes who pushed the dosage "just one more week." But separating the facts from the forum mythology requires understanding what these compounds actually do to your blood markers: and what is reversible versus what accumulates over time.
A typical Superdrol cycle at 20 mg/day will show ALT climbing from a baseline of 25-30 U/L to 150-200 U/L by the end of week 2. By week 3, AST often follows, and GGT starts creeping above 50 U/L. The real problem appears when bilirubin rises above 1.5 mg/dL, because that signals the liver's excretion pathways are backing up. Total bilirubin reaching 3.0 mg/dL with direct bilirubin around 1.8 mg/dL is the point where jaundice can become visible in the sclera — that is not a reversible nuisance, that is cholestasis in progress. The mistake is to interpret elevated ALT as the only warning sign. ALT is a leak marker, not a function marker. Bilirubin and GGT tell you whether the liver is still clearing waste, and a rise in either means stopping the compound that day, not next week, and getting in front of a licensed medical professional promptly rather than sitting on it until the next scheduled check.
The fundamental distinction when evaluating harsh orals is short-term versus long-term damage. Short-term effects: elevated liver enzymes, suppressed HDL, elevated creatinine: are predictable and largely reversible within weeks to months of discontinuation. Long-term effects: arterial stiffness, nephron loss, bile duct remodeling: accumulate over repeated cycles and may not fully reverse. Understanding this distinction is the key to deciding whether the risk is worth the reward.
Superdrol Blood Work Profile
Superdrol (methasterone) is the most hepatotoxic AAS compound in common use. Its 17α-alkylated structure, combined with its extreme potency, produces a pattern of liver stress that is qualitatively different from other orals:
The mechanism behind Superdrol's hepatotoxicity is not just the 17α-alkyl group. That group slows first-pass metabolism, but the real damage comes from oxidative stress in hepatocytes. Superdrol generates reactive oxygen species that overwhelm glutathione stores, leading to mitochondrial dysfunction and apoptosis. This is why liver enzymes can spike so fast: the damage is not a slow accumulation of stress, but a direct assault on the cells' energy production. TUDCA and NAC help, but they do not stop the process. They only buy time. The practical takeaway is that liver enzyme elevation on Superdrol is not linear. It is exponential after a certain threshold. If your ALT is 120 at week 2, do not assume it will be 240 at week 4. It could be 500. That non-linear trajectory is exactly why sticking to a short, planned duration matters more than pushing week by week to see what happens — and why a sharp jump at any point is a reason to stop rather than wait for the next scheduled draw.
ALT/AST (Superdrol Pattern)
Superdrol also aggressively suppresses HDL. Values below 15 mg/dL are standard at effective doses, and some users report HDL in single digits. This creates a dual threat: the liver is under extreme stress, and cardiovascular protection is virtually absent. The combination of hepatic injury and suppressed HDL significantly increases short-term health risk during the cycle.
The HDL suppression from Superdrol is not just a drop in total HDL. The particle size distribution shifts toward smaller, more atherogenic HDL particles. Even if your total HDL reads 15 mg/dL, the remaining particles are less functional at reverse cholesterol transport. LDL also rises, often from 100 to 160-180 mg/dL within 3 weeks. Triglycerides can double. The net effect is a lipid profile that resembles a patient with familial hypercholesterolemia. This is why a single Superdrol cycle can leave your cardiovascular risk elevated for months after the drug is gone. The HDL recovers slowly, but the arterial stiffness from a 4-week period of severe dyslipidemia does not fully reverse. If you are using Superdrol, you should check a full lipid panel at baseline, week 2, and week 4. If HDL drops below 10 mg/dL, you are in the danger zone where acute coronary events become a real possibility, not just a theoretical risk — that's a reason to stop the compound and get a licensed medical professional's input, not push toward the end of a planned cycle.
Why Superdrol Duration Matters So Much
Halotestin Blood Work Profile
Halotestin (fluoxymesterone) is a different beast from Superdrol. Its effects on liver enzymes are similarly aggressive, but its most distinguishing feature is its impact on lipids and its unique neuropsychiatric profile:
HDL (Halotestin Pattern)
Halotestin's neuropsychiatric effects: aggression, irritability, anxiety: are well-documented, but its blood work effects are equally concerning and less discussed. The compound produces rapid, profound HDL suppression that can be detected within days of the first dose. Its liver enzyme elevation is comparable to Superdrol, though the typical 2-3 week duration limits total hepatic load.
Halotestin's HDL suppression is so rapid that you can see a measurable change within 72 hours of the first dose — drops from the high 30s to single digits within 9-10 days are a documented pattern, not a gradual decline but closer to a cliff. The mechanism involves upregulation of hepatic lipase and increased clearance of HDL particles, not just reduced synthesis. This is why even short 2-week runs leave HDL suppressed for 4-6 weeks after discontinuation. The liver enzyme elevation on Halotestin is less predictable than Superdrol. Some users see ALT rise to 200 U/L, others stay under 100. But the lipid effect is universal. If you are using Halotestin for a competition, you need to accept that your HDL will likely be in single digits for the final week before the show — that is a trade-off worth weighing carefully, since for most people it will not be worth the cardiovascular stress, and dropping it entirely is always a safe way out of that trade-off.
One under-appreciated aspect of Halotestin is its effect on kidney markers. Because Halotestin is excreted renally, it contributes to a real: not just muscle-mass-driven: creatinine elevation, which is why cystatin C is worth monitoring even on short Halotestin cycles.
Creatinine elevation on Halotestin is often misinterpreted as muscle damage or high protein intake. But Halotestin directly increases creatinine production through its effect on skeletal muscle creatine metabolism, and it also reduces renal clearance of creatinine because of its structural similarity to cortisol. This means a creatinine of 1.4-1.6 mg/dL on Halotestin does not necessarily indicate kidney injury. The better marker is cystatin C, which is not affected by muscle mass. If cystatin C rises above 1.2 mg/L while on Halotestin, that is a real sign of reduced glomerular filtration. Checking cystatin C at baseline and at week 2 of any Halotestin cycle is worth building into the monitoring plan, and a rise of more than 20% from baseline is a reason to stop the compound and get a licensed medical professional's input. Also monitor blood pressure, because Halotestin can push systolic pressure above 140 mmHg even in athletes with normal baseline readings. That combination of high blood pressure and low HDL is a stroke risk worth taking seriously: stopping the compound is the safe move, and getting a licensed medical professional's input promptly is the other half of it, not something to monitor quietly on your own.
Short-Term vs. Long-Term Damage
Understanding what resolves and what accumulates is essential for risk assessment:
Short-Term vs Long-Term Effects of Harsh Orals
| Marker | Short-Term (Reversible) | Long-Term (Accumulates) |
|---|---|---|
| Liver Enzymes (AST, ALT) | Elevated — normalizes in 4-8 weeks | No permanent elevation if duration respected |
| GGT | Elevated — returns to baseline in 4-8 weeks | Repeated elevation may indicate subclinical fibrosis |
| HDL | Severely suppressed — recovers in 6-12 weeks | Repeated crashes may accelerate atherosclerosis |
| Bilirubin | Elevated — normalizes upon cessation | Repeated cholestasis may remodel bile ducts |
| Creatinine / eGFR | Acute rise — typically reversible | Nephron loss is permanent — repeated cycles reduce kidney reserve |
| Blood Pressure | Elevated — normalizes post-cycle | Arterial stiffness may persist after multiple cycles |
| Vascular Health | No acute change measurable | Endothelial function may decline with repeated use |
The Cumulative Cost
Duration Limits and Why They Exist
The recommended duration limits for these compounds are not arbitrary:
The 4-week limit is based on liver recovery kinetics. At week 4, liver enzyme elevation is typically 3-5x ULN but still on a linear trajectory. Beyond week 4, the rate of GGT and bilirubin elevation tends to accelerate as the liver's compensatory mechanisms become exhausted. Week 4-5 is where cholestatic injury becomes significantly more likely.
The acceleration of liver damage beyond week 4 is not just theoretical. The reason is that the liver's adaptive capacity, including glutathione regeneration and bile acid transport, becomes exhausted past a certain point. Once that happens, the damage becomes cholestatic, meaning bile flow is impaired. This is not just a lab value issue. Cholestasis causes itching, dark urine, and eventually jaundice. Recovery from cholestatic injury takes 8-12 weeks, and some users never fully regain baseline GGT. Extending a Superdrol cycle beyond 4 weeks trades a modest amount of additional muscle for a liver that may not fully recover — stopping on schedule, or earlier if markers are moving badly, is the safer call every time.
Halotestin's shorter limit is driven primarily by lipid toxicity rather than liver stress. HDL crash to below 10 mg/dL within 7-10 days creates acute cardiovascular risk. Beyond 2-3 weeks, the period of severe HDL suppression outweighs the anesthetic benefit for nearly all users.
What Happens When You Exceed Duration Limits
Are These Compounds Ever Worth the Risk?
This is the question every athlete faces when considering Superdrol or Halotestin. The honest answer, based on the evidence:
- For beginners and intermediates: No. These compounds offer nothing that cannot be achieved with safer alternatives (Anavar, Primobolan, nandrolone) with a fraction of the blood work risk.
- For advanced athletes with competition goals: Potentially, but only with strict duration limits, full liver support, and weekly blood work. A 3-week Halotestin run before a competition with adequate monitoring carries different risk than a 6-week "let us see what this does" experiment.
- For any athlete with pre-existing issues: No: if your baseline HDL is below 40, your GGT is elevated, or you have any history of liver or kidney issues, these compounds are contraindicated.
The deciding factor should be your blood work, not your goals. If baseline HDL is below 40 or GGT is above 40, these compounds are off the table. If you proceed, weekly blood work is non-negotiable: ALT, AST, GGT, bilirubin, HDL, and blood pressure every 7 days.